Haverkamp W, Deuschle M
Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin.
Nervenarzt. 2006 Mar;77(3):276, 278-80, 282-4 passim. doi: 10.1007/s00115-005-1966-x.
Prolongation of myocardial repolarisation, i.e. lengthening of the QT interval on surface electrocardiogram, has been recognised as a side effect of many drugs, including antipsychotics. In predisposed individuals, abnormal excessive QT prolongation and severe ventricular arrhythmias (the ventricular tachycardia type 'torsade de pointes', or TdP) may occur. In almost all cases, additional factors are present that increase the propensity of patients to develop TdP, such as serum hypokalemia, the combination of drugs prolonging repolarisation, overdosing, intoxication, and factors interfering with drug metabolism and excretion. Serum hypokalemia and/or bradycardia may induce TdP alone, in the absence of drugs prolonging the QT interval. Experimental studies demonstrate that prolongation of myocardial repolarisation is a class effect of neuroleptics. Clinically, the extent to which individual drugs prolong the QT interval varies. Among the antipsychotics, thioridazine has the greatest propensity to induce abnormal QT prolongations and TdP. Case reports of TdP with other antipsychotics have been published. Physicians prescribing physicians these drugs must be aware that they can induce proarrhythmia in individual cases. They should also be aware of the circumstances which are necessary for abnormal QT prolongation and TdP to develop. Patients should be monitored with regard to these risk factors before and during drug treatment.
心肌复极延长,即体表心电图QT间期延长,已被确认为包括抗精神病药物在内的许多药物的副作用。在易感个体中,可能会出现异常的过度QT延长和严重室性心律失常(“尖端扭转型室性心动过速”或TdP型室性心动过速)。几乎在所有情况下,都存在其他因素增加患者发生TdP的倾向,如血清低钾血症、延长复极的药物联合使用、用药过量、中毒以及干扰药物代谢和排泄的因素。血清低钾血症和/或心动过缓可能在不存在延长QT间期药物的情况下单独诱发TdP。实验研究表明,心肌复极延长是抗精神病药物的类效应。临床上,各药物延长QT间期的程度有所不同。在抗精神病药物中,硫利达嗪诱发异常QT延长和TdP的倾向最大。已发表了使用其他抗精神病药物发生TdP的病例报告。开具这些药物的医生必须意识到它们在个别情况下可诱发心律失常。他们还应了解异常QT延长和TdP发生所需的情况。在药物治疗前和治疗期间,应对患者的这些危险因素进行监测。